Vineet Gupta, PhD

Vineet Gupta studies integrin family of cellular receptors and how they can be targeted to develop novel therapeutics. His laboratory pioneered the development of allosteric agonists as a therapeutic strategy for integrins and recently demonstrated therapeutic efficacy targeting myeloid cells with this modality in human patients. To translate these discoveries into clinic, Vineet has also co-founded multiple biotech startups. His current startup, Allosite Therapeutics, is developing novels therapeutics for immune mediated diseases. His research group is studying allosteric integrin agonists as therapeutics for kidney, autoimmune and neurodegenerative diseases. Vineet obtained his PhD in Chemistry from University of Rochester and did his post-doctoral research at The Rockefeller University and at Massachusetts General Hospital, Harvard Medical School. He is currently Vice President for Innovation & Commercialization and Professor of Nephrology at University of Texas Medical Center (UTMB) and holds the Warmoth endowed Professorship in Hematology.